ASCO 2012: Metastatic castration-resistant prostate cancer; abiraterone acetate ...
Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Karim Fizazi from Institut...
ASCO 2012: Metastatic castration-resistant prostate cancer; abiraterone acetate COU-AA-302 study ( Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Karim Fizazi from Institut Gustave Roussy, France )
12 Jun 2012
ASCO 2012: Advances in pre-operative care in high-risk mCRCP
Dr Chris Parker - Royal Marsden Cancer Centre, UK; Prof Eleni Efstathiou - MD An...
ASCO 2012: Advances in pre-operative care in high-risk mCRCP ( Dr Chris Parker - Royal Marsden Cancer Centre, UK; Prof Eleni Efstathiou - MD Anderson Cancer Centre, USA )
12 Jun 2012
ASCO 2012: Advances in metastatic castration-resistant prostate cancer; first-li...
Dr Chris Parker - Royal Marsden Cancer Centre, London, UK; Prof Stéphan Oudard -...
ASCO 2012: Advances in metastatic castration-resistant prostate cancer; first-line cabazitaxel ( Dr Chris Parker - Royal Marsden Cancer Centre, London, UK; Prof Stéphan Oudard - Hôpital Européen Georges Pompidou, France )
12 Jun 2012
ASCO 2012: Advances in metastatic castration-resistant prostate cancer with abir...
Dr Karim Fizazi - Institut Gustave Roussy, France; Dr Oscar Goodman - Nevada Can...
ASCO 2012: Advances in metastatic castration-resistant prostate cancer with abiraterone ( Dr Karim Fizazi - Institut Gustave Roussy, France; Dr Oscar Goodman - Nevada Cancer Institute, USA )
12 Jun 2012
Intermittent hormonal therapy versus continuous therapy for advanced prostate ca...
Dr Maha Hussain - University of Michigan, Ann Arbor, USA
Intermittent hormonal therapy versus continuous therapy for advanced prostate cancer ( Dr Maha Hussain - University of Michigan, Ann Arbor, USA )
3 Jun 2012
Intermittent hormonal therapy less effective than continuous therapy when treati...
Dr Maha Hussain - University of Michigan, Ann Arbor, USA
Intermittent hormonal therapy less effective than continuous therapy when treating advanced prostate cancer ( Dr Maha Hussain - University of Michigan, Ann Arbor, USA )
3 Jun 2012
Early results from new PD-1 targeted immune therapy
Dr Suzanne Topalian - Johns Hopkins University School of Medicine, Baltimore, US...
Early results from new PD-1 targeted immune therapy ( Dr Suzanne Topalian - Johns Hopkins University School of Medicine, Baltimore, USA )
2 Jun 2012
New study asks patients preference on kidney cancer treatment
Dr Bernard Escudier - Institut Gustave Roussy, Paris, France
New study asks patients preference on kidney cancer treatment ( Dr Bernard Escudier - Institut Gustave Roussy, Paris, France )
2 Jun 2012
Current treatment practices in metastatic castration resistant prostate cancer
Prof Joachim Bellmunt, Prof Nicolas Mottet, Prof Noel Clarke, Prof Alfredo Berru...
Current treatment practices in metastatic castration resistant prostate cancer ( Prof Joachim Bellmunt, Prof Nicolas Mottet, Prof Noel Clarke, Prof Alfredo Berruti )
22 May 2012
Evidence for TORC1 activation marker as a predictive factor for everolimus effic...
Dr Thomas Bachelot - Centre Leon Berard, Lyon, France
Evidence for TORC1 activation marker as a predictive factor for everolimus efficacy in metastatic breast cancer ( Dr Thomas Bachelot - Centre Leon Berard, Lyon, France )
17 May 2012
Long term survival with testicular cancer
Sophie Bunskoek – University Medical Center Gronigen, The Netherlands
Long term survival with testicular cancer ( Sophie Bunskoek – University Medical Center Gronigen, The Netherlands  )
11 May 2012
Supportive care for men with prostate cancer
Jane Cockle-Hearne – University of Surrey, Guildford, UK
Supportive care for men with prostate cancer ( Jane Cockle-Hearne – University of Surrey, Guildford, UK )
10 May 2012